{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:10:36Z","timestamp":1770473436035,"version":"3.49.0"},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,5,1]]},"abstract":"<jats:p> PURPOSE: Bisphosphonates have been found to reduce the incidence of skeletal-related events (SREs) in patients with multiple myeloma. This is the first double-blind, randomized, placebo-controlled study to assess the efficacy of ibandronate, a third-generation amino-bisphosphonate, in preventing SREs in advanced-stage multiple myeloma patients. <\/jats:p><jats:p> PATIENTS AND METHODS: Patients with multiple myeloma stage II or III were randomly assigned to receive either ibandronate 2 mg or placebo as a monthly intravenous (IV) bolus injection for 12 to 24 months in addition to conventional chemotherapy. SREs such as peripheral pathologic or vertebral fractures, hypercalcemia, severe bone pain, and bone radiotherapy or surgery were analyzed. Bone-turnover markers were also studied. Finally, post hoc analyses of bone morbidity and survival were performed. <\/jats:p><jats:p> RESULTS: Ninety-nine patients per treatment group were assessable for efficacy analysis. The occurrence of SRE per patient year and the time to first SRE were not significantly different between the two treatment groups. In overall evaluation, no differences were found between the treatment groups regarding bone pain, analgesic drug use, quality of life, and median survival (33.1 v 28.2 months, respectively). Explorative post hoc analyses revealed that ibandronate patients with strongly suppressed bone-turnover markers (\u2265 30% and \u2265 50% mean reduction of serum osteocalcin and urinary C-terminal telopeptides) developed significantly less bone morbidity. Ibandronate was tolerated well during as many as 25 therapy cycles. <\/jats:p><jats:p> CONCLUSION: Monthly injections of ibandronate 2 mg IV neither reduced bone morbidity nor prolonged survival in the overall population of stage II\/III multiple myeloma patients. <\/jats:p>","DOI":"10.1200\/jco.2002.02.032","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T13:13:48Z","timestamp":1027775628000},"page":"2353-2359","source":"Crossref","is-referenced-by-count":125,"title":["Effects of Long-Term Intravenous Ibandronate Therapy on Skeletal-Related Events, Survival, and Bone Resorption Markers in Patients With Advanced Multiple Myeloma"],"prefix":"10.1200","volume":"20","author":[{"given":"Hans D.","family":"Menssen","sequence":"first","affiliation":[{"name":"From the Departments of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universit\u00e4t, and St Hedwigs-Krankenhaus, Berlin; Roche Diagnostics GmbH, Mannheim, Germany; Institute for Hematology and Blood Transfusion, Bratislava, Slovakia; C.H.R.-Claude Huriez, Lille; CHU H\u00f4pital de l\u2019Archet, Service de Rhumatologie, Nice; Centre Hospitalier, Service de M\u00e9decine Interne A, Dunkerque; and H\u00f4pital Edouard Herriot, Lyon, France; Cancer Research Center, Moscow, Russia; and Royal United Hospital, Bath,..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Sakalov\u00e1","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universit\u00e4t, and St Hedwigs-Krankenhaus, Berlin; Roche Diagnostics GmbH, Mannheim, Germany; Institute for Hematology and Blood Transfusion, Bratislava, Slovakia; C.H.R.-Claude Huriez, Lille; CHU H\u00f4pital de l\u2019Archet, Service de Rhumatologie, Nice; Centre Hospitalier, Service de M\u00e9decine Interne A, Dunkerque; and H\u00f4pital Edouard Herriot, Lyon, France; Cancer Research Center, Moscow, Russia; and Royal United Hospital, Bath,..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Fontana","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universit\u00e4t, and St Hedwigs-Krankenhaus, Berlin; Roche Diagnostics GmbH, Mannheim, Germany; Institute for Hematology and Blood Transfusion, Bratislava, Slovakia; C.H.R.-Claude Huriez, Lille; CHU H\u00f4pital de l\u2019Archet, Service de Rhumatologie, Nice; Centre Hospitalier, Service de M\u00e9decine Interne A, Dunkerque; and H\u00f4pital Edouard Herriot, Lyon, France; Cancer Research Center, Moscow, Russia; and Royal United Hospital, Bath,..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Herrmann","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universit\u00e4t, and St Hedwigs-Krankenhaus, Berlin; Roche Diagnostics GmbH, Mannheim, Germany; Institute for Hematology and Blood Transfusion, Bratislava, Slovakia; C.H.R.-Claude Huriez, Lille; CHU H\u00f4pital de l\u2019Archet, Service de Rhumatologie, Nice; Centre Hospitalier, Service de M\u00e9decine Interne A, Dunkerque; and H\u00f4pital Edouard Herriot, Lyon, France; Cancer Research Center, Moscow, Russia; and Royal United Hospital, Bath,..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Boewer","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universit\u00e4t, and St Hedwigs-Krankenhaus, Berlin; Roche Diagnostics GmbH, Mannheim, Germany; Institute for Hematology and Blood Transfusion, Bratislava, Slovakia; C.H.R.-Claude Huriez, Lille; CHU H\u00f4pital de l\u2019Archet, Service de Rhumatologie, Nice; Centre Hospitalier, Service de M\u00e9decine Interne A, Dunkerque; and H\u00f4pital Edouard Herriot, Lyon, France; Cancer Research Center, Moscow, Russia; and Royal United Hospital, Bath,..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universit\u00e4t, and St Hedwigs-Krankenhaus, Berlin; Roche Diagnostics GmbH, Mannheim, Germany; Institute for Hematology and Blood Transfusion, Bratislava, Slovakia; C.H.R.-Claude Huriez, Lille; CHU H\u00f4pital de l\u2019Archet, Service de Rhumatologie, Nice; Centre Hospitalier, Service de M\u00e9decine Interne A, Dunkerque; and H\u00f4pital Edouard Herriot, Lyon, France; Cancer Research Center, Moscow, Russia; and Royal United Hospital, Bath,..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michail R.","family":"Lichinitser","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universit\u00e4t, and St Hedwigs-Krankenhaus, Berlin; Roche Diagnostics GmbH, Mannheim, Germany; Institute for Hematology and Blood Transfusion, Bratislava, Slovakia; C.H.R.-Claude Huriez, Lille; CHU H\u00f4pital de l\u2019Archet, Service de Rhumatologie, Nice; Centre Hospitalier, Service de M\u00e9decine Interne A, Dunkerque; and H\u00f4pital Edouard Herriot, Lyon, France; Cancer Research Center, Moscow, Russia; and Royal United Hospital, Bath,..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.R.J.","family":"Singer","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universit\u00e4t, and St Hedwigs-Krankenhaus, Berlin; Roche Diagnostics GmbH, Mannheim, Germany; Institute for Hematology and Blood Transfusion, Bratislava, Slovakia; C.H.R.-Claude Huriez, Lille; CHU H\u00f4pital de l\u2019Archet, Service de Rhumatologie, Nice; Centre Hospitalier, Service de M\u00e9decine Interne A, Dunkerque; and H\u00f4pital Edouard Herriot, Lyon, France; Cancer Research Center, Moscow, Russia; and Royal United Hospital, Bath,..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana","family":"Euller-Ziegler","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universit\u00e4t, and St Hedwigs-Krankenhaus, Berlin; Roche Diagnostics GmbH, Mannheim, Germany; Institute for Hematology and Blood Transfusion, Bratislava, Slovakia; C.H.R.-Claude Huriez, Lille; CHU H\u00f4pital de l\u2019Archet, Service de Rhumatologie, Nice; Centre Hospitalier, Service de M\u00e9decine Interne A, Dunkerque; and H\u00f4pital Edouard Herriot, Lyon, France; Cancer Research Center, Moscow, Russia; and Royal United Hospital, Bath,..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Wetterwald","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universit\u00e4t, and St Hedwigs-Krankenhaus, Berlin; Roche Diagnostics GmbH, Mannheim, Germany; Institute for Hematology and Blood Transfusion, Bratislava, Slovakia; C.H.R.-Claude Huriez, Lille; CHU H\u00f4pital de l\u2019Archet, Service de Rhumatologie, Nice; Centre Hospitalier, Service de M\u00e9decine Interne A, Dunkerque; and H\u00f4pital Edouard Herriot, Lyon, France; Cancer Research Center, Moscow, Russia; and Royal United Hospital, Bath,..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Fiere","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universit\u00e4t, and St Hedwigs-Krankenhaus, Berlin; Roche Diagnostics GmbH, Mannheim, Germany; Institute for Hematology and Blood Transfusion, Bratislava, Slovakia; C.H.R.-Claude Huriez, Lille; CHU H\u00f4pital de l\u2019Archet, Service de Rhumatologie, Nice; Centre Hospitalier, Service de M\u00e9decine Interne A, Dunkerque; and H\u00f4pital Edouard Herriot, Lyon, France; Cancer Research Center, Moscow, Russia; and Royal United Hospital, Bath,..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikul\u00e1s","family":"Hrubisko","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universit\u00e4t, and St Hedwigs-Krankenhaus, Berlin; Roche Diagnostics GmbH, Mannheim, Germany; Institute for Hematology and Blood Transfusion, Bratislava, Slovakia; C.H.R.-Claude Huriez, Lille; CHU H\u00f4pital de l\u2019Archet, Service de Rhumatologie, Nice; Centre Hospitalier, Service de M\u00e9decine Interne A, Dunkerque; and H\u00f4pital Edouard Herriot, Lyon, France; Cancer Research Center, Moscow, Russia; and Royal United Hospital, Bath,..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eckhard","family":"Thiel","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universit\u00e4t, and St Hedwigs-Krankenhaus, Berlin; Roche Diagnostics GmbH, Mannheim, Germany; Institute for Hematology and Blood Transfusion, Bratislava, Slovakia; C.H.R.-Claude Huriez, Lille; CHU H\u00f4pital de l\u2019Archet, Service de Rhumatologie, Nice; Centre Hospitalier, Service de M\u00e9decine Interne A, Dunkerque; and H\u00f4pital Edouard Herriot, Lyon, France; Cancer Research Center, Moscow, Russia; and Royal United Hospital, Bath,..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre D.","family":"Delmas","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universit\u00e4t, and St Hedwigs-Krankenhaus, Berlin; Roche Diagnostics GmbH, Mannheim, Germany; Institute for Hematology and Blood Transfusion, Bratislava, Slovakia; C.H.R.-Claude Huriez, Lille; CHU H\u00f4pital de l\u2019Archet, Service de Rhumatologie, Nice; Centre Hospitalier, Service de M\u00e9decine Interne A, Dunkerque; and H\u00f4pital Edouard Herriot, Lyon, France; Cancer Research Center, Moscow, Russia; and Royal United Hospital, Bath,..."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-107525","unstructured":"Sporn  JR,   McIntyre  OR:   Chemotherapy of previously untreated multiple myeloma patients:  An analysis of recent treatment results.   Semin Oncol 13:  318,1986-325,"},{"key":"R2-107525","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(89)90001-1"},{"key":"R3-107525","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"R4-107525","unstructured":"Alexanian  R,   Dimopoulos  MA:   Management of multiple myeloma.  Semin Hematol 32:  20,1995-30,"},{"key":"R6-107525","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118722"},{"key":"R7-107525","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931201)72:11+<3443::AID-CNCR2820721611>3.0.CO;2-3"},{"key":"R8-107525","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.2713086.x"},{"key":"R9-107525","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400892"},{"key":"R10-107525","doi-asserted-by":"crossref","unstructured":"Singer  FR,   Clemens  TL,   Eusebio  RA,  et al:  Risedronate, a highly effective oral agent in the treatment of patients with severe Paget\u2019s disease.  J Clin Endocrinol Metab 83:  1906,1998-1910,","DOI":"10.1210\/jc.83.6.1906"},{"key":"R11-107525","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511303332201"},{"key":"R12-107525","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807303390502"},{"key":"R13-107525","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199612123352401"},{"key":"R14-107525","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808063390601"},{"key":"R15-107525","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1674::AID-CNCR18>3.0.CO;2-X"},{"key":"R16-107525","doi-asserted-by":"crossref","unstructured":"Riccardi  A,   Ucci  G,   Brugnatelli  S,  et al:  A prospective, controlled, non-randomized study on prophylactic pareneral dichloromethylene bisphosphonate (clodronate) in multiple myeloma.  Int J Oncol 5:  833,1994-839,","DOI":"10.3892\/ijo.5.4.833"},{"key":"R17-107525","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340802"},{"key":"R18-107525","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00567.x"},{"key":"R19-107525","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.593"},{"key":"R20-107525","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"R21-107525","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y"},{"key":"R22-107525","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F"},{"key":"R23-107525","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1969.03160090040009"},{"key":"R24-107525","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03490200198025"},{"key":"R25-107525","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.334"},{"key":"R26-107525","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"R27-107525","doi-asserted-by":"crossref","unstructured":"Hughes  DE,   Wright  KR,   Uy  HL:   Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.  J Bone Miner Res 10:  1478,1995-1487,","DOI":"10.1002\/jbmr.5650101008"},{"key":"R28-107525","doi-asserted-by":"crossref","unstructured":"Abildgaard  N,   Rungby  J,   Glerup  H,  et al:  Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma.  Eur J Haematol 61:  128,1998-134,","DOI":"10.1111\/j.1600-0609.1998.tb01073.x"},{"key":"R29-107525","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.8.1397"},{"key":"R30-107525","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93075-X"},{"key":"R31-107525","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00695.x"},{"key":"R32-107525","doi-asserted-by":"crossref","unstructured":"Muhlbauer  RC,   Bauss  F,   Schenk  R,  et al:  BM21.0955, a potent new bisphosphonate to inhibit bone resorption.  J Bone Miner Res 6:  1003,1991-1011,","DOI":"10.1002\/jbmr.5650060915"},{"key":"R33-107525","unstructured":"Body  JJ,   Lichinitser  MR,   Diehl  I,  et al:  Double blind-placebo controlled trial of intravenous ibandronate in breast cancer metastatic to bone.  Proc Am Soc Clin Oncol 35:  575a,1999  (abstr 2222)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.02.032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:56:08Z","timestamp":1653515768000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.02.032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,1]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,5,1]]}},"alternative-id":["10.1200\/JCO.2002.02.032"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.02.032","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,1]]}}}